

In the Specification:

On page 171, at lines 1 and 2, please delete the present title and substitute the following title in place thereof.

-- PROTEINS HAVING DIAGNOSTIC, PREVENTIVE,
THERAPEUTIC, AND OTHER USES --

In the Claims:

Please cancel claims 1-7 and 11-23, without prejudice to including the subject matter of the canceled claims in one or more additional patent applications.

Please amend claims 8 and 9 to read as follows. For the Examiner's convenience a "Marked-Up Copy of Claims Amended in the Response to Restriction Requirement and Preliminary Amendment" accompanies this Amendment. In that document, text which has been added to the claims is underlined, and text which has been deleted from the claims is ~~struck through~~.

Sub B1

8. (Amended) An isolated polypeptide selected from the group consisting of:

a) a fragment of a polypeptide which has an amino acid sequence comprising any of SEQ ID NOs: 47-52 and the amino acid sequence encoded by a cDNA of the clone deposited as ATCC[®] 207220, wherein the fragment comprises at least 40 contiguous amino acids of either of SEQ ID NO: 47 and the amino acid sequence encoded by a cDNA of the clone deposited as ATCC[®] 207220;

b) a naturally occurring allelic variant of a polypeptide that has an amino acid sequence comprising any of SEQ ID NOs: 47-52 and the amino acid sequence encoded by a cDNA of the clone deposited as ATCC[®] 207220, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule having the nucleotide sequence of any of

SEQ ID NOs: 45 and 46, a cDNA of the clone deposited as ATCC[®] 207220, or a complement thereof under stringent conditions; and

Al
B1
cont

c) a polypeptide which is encoded by a nucleotide sequence having a portion which is at least 90% identical to any of SEQ ID NOs: 45 and 46, the nucleotide sequence of a cDNA of the clone deposited as ATCC[®] 207220, or a complement thereof.

9. (Amended) The isolated polypeptide of claim 8, having the amino acid sequence of any of SEQ ID NOs: 47-52 and the amino acid sequence encoded by a cDNA of the clone deposited as ATCC[®] 207220, or a complement thereof.

Please add claims 24-46 as follows.

Al
B2

-- 24. The isolated polypeptide of claim 8,

wherein the isolated polypeptide is a fragment of a polypeptide which has an amino acid sequence comprising any of SEQ ID NOs: 47-52 and the amino acid sequence encoded by a cDNA of the clone deposited as ATCC[®] 207220, and

wherein the sequence of the fragment comprises at least 40 contiguous amino acids of SEQ ID NO: 47.

a2

25. The isolated polypeptide of claim 24, wherein the sequence of the fragment comprises at least 75 contiguous amino acids of SEQ ID NO: 47.

26. The isolated polypeptide of claim 24, wherein the sequence of the fragment comprises at least 150 contiguous amino acids of SEQ ID NO: 47.

27. The isolated polypeptide of claim 24, wherein the isolated polypeptide exhibits lipase activity.

Sub B3

28. The isolated polypeptide of claim 24, wherein the isolated polypeptide exhibits a property selected from the group consisting of

- i) ability to modulate absorption of a lipid;
- ii) ability to modulate metabolism of a lipid; and
- iii) ability to modulate transport of a lipid.

29. The isolated polypeptide of claim 24, admixed with a pharmaceutically acceptable carrier.

Sub B4

30. The isolated polypeptide of claim 8,

wherein the isolated polypeptide is a naturally occurring allelic variant of a polypeptide that has an amino acid sequence comprising any of SEQ ID NOs: 47-52 and the amino acid sequence encoded by a cDNA of a clone deposited as ATCC[®] 207220, and

wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to a nucleic acid molecule having the nucleotide sequence of any of SEQ ID NOs: 45 and 46, a cDNA of the clone deposited as ATCC[®] 207220, or a complement thereof under stringent conditions.

a2
cont.

31. The isolated polypeptide of claim 30, wherein the stringent conditions comprise hybridization in $6 \times$ sodium chloride/sodium citrate buffer (SSC) at about 45°C, followed by washing in $0.2 \times$ SSC comprising 0.1% SDS at 65°C.

32. The isolated polypeptide of claim 30, wherein the isolated polypeptide exhibits lipase activity.

33. The isolated polypeptide of claim 30, wherein the isolated polypeptide exhibits a property selected from the group consisting of:

- i) ability to modulate absorption of a lipid;
- ii) ability to modulate metabolism of a lipid; and
- iii) ability to modulate transport of a lipid.

34. The isolated polypeptide of claim 30, admixed with a pharmaceutically acceptable carrier.

See B5

35. The isolated polypeptide of claim 8, wherein the isolated polypeptide is encoded by a nucleotide sequence having a portion which is at least 90% identical to any of SEQ ID NOs: 45 and 46, the nucleotide sequence of a cDNA of the clone deposited as ATCC® 207220, or a complement thereof.

36. The isolated polypeptide of claim 35, wherein the portion is at least 95% identical to SEQ ID NO: 46.

*a2:
cont.*

37. The isolated polypeptide of claim 35, wherein the isolated polypeptide exhibits lipase activity.

38. The isolated polypeptide of claim 35, wherein the isolated polypeptide exhibits a property selected from the group consisting of

- i) ability to modulate absorption of a lipid;
- ii) ability to modulate metabolism of a lipid; and
- iii) ability to modulate transport of a lipid.

39. The isolated polypeptide of claim 35, admixed with a pharmaceutically acceptable carrier.

40. The isolated polypeptide of claim 9, having the amino acid sequence of SEQ ID NO: 47.

41. The isolated polypeptide of claim 9, having the amino acid sequence of SEQ ID NO: 49.

42. An isolated polypeptide that exhibits lipase activity, wherein the amino acid sequence of the isolated polypeptide comprises a portion that is at least 90% identical to 150 contiguous amino acid residues of SEQ ID NO: 47.

43. The isolated polypeptide of claim 42, wherein the portion is at least 95% identical to 200 contiguous amino acid residues of SEQ ID NO: 49.

44. The isolated polypeptide of claim 42, wherein the amino acid sequence of the isolated polypeptide is at least 90% identical to any one of SEQ ID NO: 47, residues 15-423 of SEQ ID NO: 47, and SEQ ID NO: 49.

45. The isolated polypeptide of claim 42, admixed with a pharmaceutically acceptable carrier.

46. An isolated polypeptide that exhibits a property selected from the group consisting of

- i) ability to modulate absorption of a lipid;
- ii) ability to modulate metabolism of a lipid; and
- iii) ability to modulate transport of a lipid,

wherein the amino acid sequence of the isolated polypeptide comprises a portion that is at least 90% identical to 150 contiguous amino acid residues of SEQ ID NO: 47. --

a2
cont.

add BB